Ranbaxy Laboratories Ltd is in talks with Specialty Laboratories Inc of the US to buy out its stake in Speciality Ranbaxy Ltd (SRL), a 50:50 joint venture.
According to sources, the American company has expressed its intention to pull out from the venture and the two partners are in negotiation to this effect. Ranbaxy as well as Speciality Laboratories own 6.52 million shares in the company.
SRL is a research-based clinical reference laboratory which develops and provides incisive diagnostic, prognostic, and monitoring services. It has clocked a turnover of Rs 30 crore during 2000-01.
Also Read
In the current financial year, it plans to grow at a faster rate than the 25 per cent expected by the industry. The company has over 1,000 products in its portfolio and caters to almost all segments of the market. SRL is the single largest source of specialised medical testing facility in South East Asia.
According to sources, the American partner's pull-out decision has been prompted by the vast differences between the Indian and the US markets. "Besides, it is doing very well there," sources said.
SRL functionaries added that the company's dependence on the US company is minimal and it is capable of running on its own. "SRL has adapted the standards of Speciality Laboratories and is self-sufficient in all matters," the sources added.
Operating through 500 collection centres all over the country, SRL has accreditation from NABL, a government body. It has two labs in the country, one in Mumbai and the other in Bangalore. It is setting up two more labs, one each at Mohali and Delhi. The SRL Lab in Mumbai has got the Gold Standard, the only laboratory in the country to receive it.
Specialty Laboratories began operations in 1977 in the fields of immunology and rheumatology and quickly gained a reputation for leadership in the development of new and reliable assays.
Applying the same rigorous standards to other clinical disciplines, Specialty Laboratories expanded into a full-service reference laboratory meeting the medical testing needs of its diverse clientele.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
